FIRST AMENDMENT TO COLLABORATION AGREEMENTCollaboration Agreement • November 5th, 2020 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This First Amendment to Collaboration Agreement (this “Amendment”) is made and entered into as of date of the last Party signing this Amendment (the “Amendment Effective Date”), by and between Kymera Therapeutics, Inc. (“Kymera”), and GlaxoSmithKline Intellectual Property Limited (“GSK”) and amends that certain Collaboration Agreement (the “Agreement”), dated as of October 3, 2017 by and between Kymera (formerly known as Project Chimera, Inc.) and GSK.
FIRST AMENDMENT TO MASTER COLLABORATION AGREEMENTMaster Collaboration Agreement • November 5th, 2020 • Kymera Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment to Master Collaboration Agreement (this “Amendment”) is made and entered into as of August 27, 2020 (the “Amendment Effective Date”), by and between and Vertex Pharmaceuticals Incorporated (“Vertex”) and Kymera Therapeutics, Inc. (“Company”), and amends that certain Master Collaboration Agreement (the “Agreement”), dated as of May 9, 2019 by and between Vertex and Company. All capitalized terms used, but not otherwise defined, in this Amendment shall have the meaning given to them in the Agreement.
